Table 2.

Response rates – at 3, 6, 12, 18, 24 and 30 months of dasatinib at 50mg daily^*

No. Response/Total (%)	3 months	6 months	12 months	18 months	24 months	30 months
BCR-ABL1 transcripts (IS) ≤10%	78/81 (96)	79/81 (98)	---	---	---	---
PCR ≤1%	62/81 (77)	73/81 (88)	---	---	---	---
CCyR	40/81 (49)	70/81 (86)	76/81 (94)	61/65 (94)	44/47 (94)	18/18 (100)
MMR	27/81 (33)	53/81 (65)	65/81 (80)	57/65 (88)	41/47 (87)	18/18 (100)
MR4.0	5/81 (6)	28/81 (35)	48/81 (59)	48/65 (74)	31/47 (66)	15/18 (83)
MR4.5	3/81 (4)	21/81 (26)	40/81 (49)	44/65 (68)	27/47 (57)	14/18 (78)

CCyR=complete cytogenetic response; MMR=major molecular response (BCR-ABL1 transcripts [IS] ≤0.1%); MR4.0 = BCR-ABL transcripts (IS) ≤0.01%; MR4.5 = BCR-ABL transcripts (IS) ≤0.0032%

^*As the data matured showing discrepancy between PCR and FISH testing at 3 months, BCR-ABL1 transcripts (IS) ≤1% was used to define CCyR. In addition cytogenetic assessment by conventional cytogenetics was mandated at 6 months, starting patient 19 and onwards.